Get startedLog in
    Picture of Lantern Pharma logo

    LTRN — Lantern Pharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Lantern Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

    Picture of Lantern Pharma logoLantern Pharma
    27/03/2025 21:00
    Lantern Pharma Inc LTRN.OQ reported a quarterly adjusted loss of 54 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -39 cents.  The lone analyst forecast for the quarter was for a loss of 51 cents per share.

Reported revenue was zero​; analysts expected zero.

Lantern Pharma Inc's reported EPS for the quarter was a loss of 54 cents​.

The company reported a quarterly loss of $5.88 million.

Lantern Pharma Inc shares had risen by 14.4% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Lantern Pharma Inc is $20.50

This summary was machine generated from LSEG data March 27 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)


    QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
    Dec. 31 2024-0.51-0.54Missed
    Sep. 30 2024-0.56-0.42Beat
    Jun. 30 2024-0.55-0.46Beat
    Mar. 31 2024-0.43-0.51Missed

    Recent news on Lantern Pharma

    See all news